# GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

> **NCT07087002** · PHASE1 · RECRUITING · sponsor: **Stanford University** · enrollment: 18 (estimated)

## Conditions studied

- Medulloblastoma
- Central Nervous System Embryonal Tumor
- Refractory Medulloblastoma
- Recurrent Medulloblastoma
- Pediatric Brain Tumor
- Embryonal Tumor With Multilayered Rosettes (ETMR)
- Pineoblastoma
- Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS
- CNS Neuroblastoma
- FOXR2-activated

## Interventions

- **BIOLOGICAL:** GPC2-CAR T cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT07087002
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-28
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07087002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07087002, "GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07087002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*